Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
laser decrease » linear decrease (Expand Search), water decreases (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
laser decrease » linear decrease (Expand Search), water decreases (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
145041
Image_1_Prolactin does not seem to mediate the improvement on insulin resistance markers and blood glucose levels related to breastfeeding.jpeg
Published 2023“…</p>Methods<p>The prospective study followed 95 women older than 18 years from early pregnancy for up to 60 to 180 days postpartum. All participants had a BMI > 25 kg/m<sup>2</sup> and a singleton pregnancy. …”
-
145042
Respiratory symptoms-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
145043
Other symptoms-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
145044
Bias risk assessment for individual studies.
Published 2023“…<div><p>Objective</p><p>To systematically evaluate the efficacy and safety of Sodium tanshinone ⅡA sulfonate injection (STS) in the treatment of unstable angina pectoris (UAP).…”
-
145045
Sustained-release of phages targets <i>E</i>. <i>faecalis</i> biofilm.
Published 2019“…<p><b>(A) <i>E</i>. <i>faecalis</i> biofilm biomass decreased following treatment with sustained-release EFDG1/EFLK1 phage cocktail.…”
-
145046
Data_Sheet_2_Integrating Ligand and Target-Driven Based Virtual Screening Approaches With in vitro Human Cell Line Models and Time-Resolved Fluorescence Resonance Energy Transfer A...
Published 2020“…In the first approach, a molecular docking and filtering approach is used to rank compounds based on their docking scores and only a few top-ranked molecules are selected for further long (100-ns) molecular dynamics (MD) simulations and in vitro tests. …”
-
145047
The Effect of Symmetric and Asymmetric NHCs on the Structure and Catalytic Properties of Dialkylgallium Alkoxides in the Ring-Opening Polymerization of <i>rac</i>-LactideLinking t...
Published 2021“…The much smaller cavity of <b>4</b> led to a minor activity and lower isoselectivity (<i>P</i><sub>m‑max</sub> = 0.56 at −20 °C). …”
-
145048
Expression of mesoderm and primitive streak markers in <i>Cul4b</i>-null embryos.
Published 2019“…(C, D) A slight decrease in Brachyury was detected at E7.5 in <i>Cul4b</i><sup><i>Δ/</i></sup><i>Y</i> embryos. …”
-
145049
Diarrhea-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
145050
Gastrointestinal symptoms-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
145051
Subgroup analysis of angina pectoris attack time.
Published 2023“…<div><p>Objective</p><p>To systematically evaluate the efficacy and safety of Sodium tanshinone ⅡA sulfonate injection (STS) in the treatment of unstable angina pectoris (UAP).…”
-
145052
Nausea-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
145053
Retinoic acid signaling responsiveness in the periocular region.
Published 2020“…BMS493 treatment before and after tamoxifen induction reveals a drastic decrease in GFP+ cells in the periocular region (<b>I</b>) compared with controls (<b>G</b>). …”
-
145054
Safety and EEG data quality of concurrent high-density EEG and high-speed fMRI at 3 Tesla
Published 2017“…The degree of artifacts and the ability to identify background activity was assessed by visual analysis by a trained expert in the 64 channel EEG data (7 healthy controls, 13 patients).…”
-
145055
Meta-analysis off requency of angina attacks.
Published 2023“…<div><p>Objective</p><p>To systematically evaluate the efficacy and safety of Sodium tanshinone ⅡA sulfonate injection (STS) in the treatment of unstable angina pectoris (UAP).…”
-
145056
Flow of patients in Halos trial.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
145057
Meta-analysis of angina pectoris attack time.
Published 2023“…<div><p>Objective</p><p>To systematically evaluate the efficacy and safety of Sodium tanshinone ⅡA sulfonate injection (STS) in the treatment of unstable angina pectoris (UAP).…”
-
145058
Cough-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
145059
Supplementary Figures from Lipidomic Profiling Links the Fanconi Anemia Pathway to Glycosphingolipid Metabolism in Head and Neck Cancer Cells
Published 2023“…*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (two-tailed t test) Supplementary Figure 5 Ganglioside GM3 (d34:1), GM3 (d34:0) and GM3 (d34:2) decrease in NTsh, FANCD2sh and FANCJsh UMSCC-1 cells after NB-DNJ exposure Supplementary Figure 6 NTsh and FANCD2sh NIKS cells (a) and UMSCC-47 cells (b) were plated at equal cell numbers, and NB-DNJ was added following cell attachment, and replenished in fresh media after 24 hrs</p>…”
-
145060
Dyspnea-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”